HEATR1, ZNF185, and SMAD4 could affect the chemosensitivity of gemcitabine and may be the indicators of gemcitabine selection in the chemotherapy of pancreatic cancer. The gene discussed is SMAD4; the disease is familial pancreatic carcinoma.